Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
Patents for C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
05/2010
05/27/2010WO2010057833A1 Compounds for treatment of duchenne muscular dystrophy
05/27/2010WO2010057430A1 Polymorph form l of erlotinib, methods of preparation and uses thereof
05/27/2010WO2010038081A3 4-amino-5- (hetero) aryl-2-phenylamino-pyrimidine or pyridine and their use as dna gyrase and/or topoisomerase iv inhibitors
05/27/2010US20100130743 Heterocycle-substituted, n-phenyl-phthalamide derivatives, related compounds and their use as insecticides
05/27/2010US20100130742 Tetralin and indane derivatives and uses thereof
05/27/2010US20100130741 Process for erlotinib hydrochloride
05/27/2010US20100130739 Nitrogen-containing six-membered aromatic ring derivatives and pharmaceutical products containing the same
05/27/2010US20100130501 Novel 3-amino-pyrrolo[3,4-c]pyrazole-5(1h, 4h, 6h) carbaldehyde derivatives
05/27/2010US20100130458 Polymorphs of fluticasone furoate and process for preparation thereof
05/27/2010US20100130440 Antiviral nucleosides
05/27/2010US20100130432 Non-Natural Amino Acids and Neurotensin Analogues Thereof
05/27/2010US20100127213 Liquid crystalline medium and liquid crystal display
05/27/2010CA2744351A1 New compounds
05/27/2010CA2743562A1 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
05/27/2010CA2742023A1 Polar quinazolines as liver x receptors ( lxrs ) modulators
05/26/2010EP2189503A1 Novel nucleic acid derivative into which given compound has been introduced and method for producing the same
05/26/2010EP2189450A1 Method for producing quinazoline derivative
05/26/2010EP2189440A1 Tricyclic amine compound
05/26/2010EP2188265A1 Process for preparation of amorphous lopinavir
05/26/2010EP2188254A1 Novel bradykinin b1-antagonists
05/26/2010EP1622881B1 Quinazolinone-derivatives and their use for preparation of pharmaceutical compositions having parp enzyme inhibitory effect
05/26/2010EP1303495B1 Substituted 5-alkynyl pyrimidines having neurotrophic activity
05/26/2010CN1805748B 2-aminopyrimidine derivatives as RAF kinase inhibitors
05/26/2010CN1746168B Optically active doxazosin
05/26/2010CN1665507B Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
05/26/2010CN1656073B Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
05/26/2010CN1520702B Electroluminescent irisium compounds with fluorinated phenylpyridines, phenylpyridines and phenylquinolines and device made with such compounds
05/26/2010CN1391469B Npyy5拮抗剂 Npyy5 antagonist
05/26/2010CN1359390B Factor VII a inhibitors
05/26/2010CN101715442A Heterocyclic aspartyl protease inhibitors
05/26/2010CN101712657A heteroarylcarbamoylbenzene derivative
05/26/2010CN101712654A Liquid crystal compound containing fluoropyrimidine and application thereof
05/26/2010CN101712632A Substituted tetracycline compounds
05/26/2010CN101712585A Organic-matter nitrosoation method with no production of nitric oxide waste gas
05/26/2010CN101205215B Method for preparing cidofovir key intermediate
05/25/2010US7723522 Pyridine derivative production method
05/25/2010US7723519 high binding efficiencies between D3 and D2 dopaminergic receptor subtypes; drug abuse, drug dependence
05/25/2010US7723494 Yellow anionic disazo dyes
05/25/2010US7723380 Tetrahydrofuro[2,3-b]furyl carbamates containing an (oxy)hydrazide group; these compounds target the HIV protease in both wild type and mutant strains of HIV.
05/25/2010US7723362 for controlling acarina
05/25/2010US7723346 for treatment of focal distonia, tremors, and parkinson's disease; administering sodium salt of 5,5-diphenyl barbituric acid
05/25/2010US7723345 Multicyclic amino acid derivatives and methods of their use
05/25/2010US7723344 Dipeptidyl peptidase inhibitors
05/25/2010US7723340 mitogen-activated protein kinase 8 inhibitors, used for treating or preventing cancer, cardiovascular diseases, renal diseases, autoimmune disorders, inflammatory disorders, vision defects, ischemia-reperfusion injuries, pain and hypertension
05/25/2010US7723339 signal transduction inhibitor is a PDGF receptor tyrosine kinase inhibitor or an active ingredient which decreases the activity of the epidermal growth factor; antiproliferative agent
05/25/2010US7723333 used in treating and/or preventing cardiovascular disorders, inflammatory diseases, Alzheimer's disease, dyslipidemia and metabolic syndrome
05/25/2010US7723267 Substituted fluoroalcoxyphenylsulfonylurea
05/25/2010US7723266 Such as N-(4,6-dimethoxy-pyrimidin-2-yl)-N'-(2-ethoxy-6-methyl-phenylsulphonyl)-urea; activity; crop plant safety; synthesis
05/25/2010US7722893 Use of substitute 2,4-bis (alkylamino) pyrimidines or quinzolines as antimicrobials
05/25/2010CA2493794C Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
05/25/2010CA2248303C Perfluorinated amide salts and their uses as ionic conducting materials
05/20/2010WO2010056992A1 Methods of preventing and treating low bone mass diseases
05/20/2010WO2010056230A1 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
05/20/2010WO2010055117A1 2,4-diaminopyrimidine derivates as ptk2- inhibitors for the treatment of abnormal cell growth
05/20/2010WO2010055006A1 Naphthylacetic acids used as crth2 antagonists or partial agonists
05/20/2010US20100125139 Process for preparing quinazoline rho-kinase inhibitors and intermediates thereof
05/20/2010US20100125075 Antibacterial Agents
05/20/2010CA2743073A1 2,4-diaminopyrimidine derivates as ptk2- inhibitors for the treatment of abnormal cell growth
05/20/2010CA2740389A1 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
05/20/2010CA2739725A1 Naphthylacetic acids used as crth2 antagonists or partial agonists
05/19/2010EP2186901A2 Mutations in the BCR-Abl-tyrosine kinase associated with resistance to STI-571
05/19/2010EP2185528A1 Process for the preparation of methyl ester of rosuvastatin
05/19/2010EP2185523A2 Derivatives of 1-oxo-1,2-dihydroisoquinoline-5-carboxamides and of 4-oxo-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics
05/19/2010EP2185518A2 Saturated and insaturated bi- or tricyclic aryloxyacetamide derivatives and their use as fungicides
05/19/2010EP1856059B1 Multimers of pyrimidinone derivatives and their use as human neutrophil elastase inhibitors
05/19/2010EP1706372B1 Alpha-hydroxy amides as bradykinin antagonists or inverse agonists
05/19/2010EP1371646B1 Aryl-substituted alicyclic compound and medical composition comprising the same
05/19/2010CN101119961B Substituted P-trifluoromethyl phenylethers, the preparatio and the use thereof
05/19/2010CN101029065B Bean-curd pectin analogue and its use in medicine for preventing depression
05/18/2010US7718801 Anticancer agents; PLK1 inhibitors; PLK=polo-like kinase; imidazo(1,2-a)pyridines such as 5-bromo-4-[8-(difluoromethyl)imidazo[1,2-a]pyridin-3-yl]-N-[(1S)-1-phenylethyl]-2-pyrimidinamine
05/18/2010US7718722 Alkylthio- and aryl(heteroyl)thio-substituted p-phenylenediamines, their manufacture and their use in rubber
05/18/2010US7718702 Cannabinoid receptor ligands
05/18/2010US7718675 Diamino alcohols and their use as renin inhibitor
05/18/2010US7718663 Quinazoline derivatives and medicaments
05/18/2010US7718658 Saturated ring with 2 nitrogens, 1 of which is 2-(o-(difluoromethyl)phenyl)quinazol-4-yl-substituted and the other is oxyalkanoyl-substituted; inhibitors of voltage-gated sodium channels and calcium channels; treating acute, chronic, neuropathic, or inflammatory pain
05/18/2010CA2422371C Pyrazole compounds useful as protein kinase inhibitors
05/18/2010CA2422367C Pyrazole compounds useful as protein kinase inhibitors
05/18/2010CA2387536C Rate-controlled particles
05/18/2010CA2304204C Quinoline-containing .alpha.-ketoamide cysteine and serine protease inhibitors
05/14/2010WO2010054042A2 Dimethylphenoxy modulators of viral protease activity and/or parasitic enzyme activity
05/14/2010WO2010051926A2 New halogen-substituted bonds
05/14/2010WO2010051819A1 Novel 2,3-diamino-quinazolinone derivatives and their medical use
05/14/2010WO2010017387A3 Lapatinib, salts thereof, processes and intermediates for their preparation
05/14/2010CA2742435A1 New halogen-substituted compounds
05/13/2010US20100121061 Compounds capable of activating cholinergic receptors
05/13/2010US20100121060 Hiv inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines
05/13/2010US20100121058 2-(substituted phenyl)-6-amino-5-alkoxy, thioalkoxy and aminoalkyl-4-pyrimidinecarboxylates and their use as herbicides
05/13/2010US20100121052 Novel compounds for treating proliferative diseases
05/13/2010US20100120804 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
05/13/2010US20100120803 3,4-dihydroquinazoline derivatives
05/13/2010US20100120802 Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production
05/13/2010US20100120793 Pyrrolidines
05/13/2010US20100120742 Rexinoid compound having alkoxy group
05/13/2010US20100120722 Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
05/13/2010US20100120719 Lyophilization formulation
05/13/2010US20100120714 Substituted benzene fungicides
05/13/2010US20100119624 Benzisoxazole modulators of d2 receptor and/or 5-ht2a receptor
05/12/2010EP2184277A1 Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof
05/12/2010EP2184273A1 Halogen substituted compounds as pesticides
05/12/2010EP2183226A2 Processes for the preparation of crystalline forms a, b and pure crystalline form a of erlotinib hcl
1 ... 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 ... 427